Loading...
XLONPOLX
Market cap19mUSD
Dec 24, Last price  
1.30GBP
1D
2.36%
1Q
-17.72%
IPO
-91.88%
Name

Polarean Imaging PLC

Chart & Performance

D1W1MN
XLON:POLX chart
P/E
P/S
2,207.36
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
29.14%
Rev. gr., 5y
-18.24%
Revenues
891k
-13.75%
880,6451,237,1632,439,1392,301,0931,056,7671,185,4271,033,008890,933
Net income
-12m
L-15.95%
-1,059,713-3,957,692-5,642,530-6,195,018-6,554,253-13,715,562-14,140,622-11,884,803
CFO
-10m
L-14.87%
-759,987-2,615,691-4,676,346-4,565,709-5,794,698-12,250,467-12,258,031-10,434,998
Earnings
Jun 26, 2025

Profile

Polarean Imaging plc operates as a medical drug-device combination company serving the medical imaging market in the United States, Canada, Germany, and the United Kingdom. The company engages in the development and commercialization of gas polarizer devices and ancillary instruments. It develops equipment that enables existing magnetic resonance imaging (MRI) systems to achieve a level of pulmonary functional imaging and specializes in the use of hyperpolarized xenon gas (129Xe) as an imaging agent to visualize ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream, and in the pulmonary vasculature; and a novel diagnostic approach. The company is also involved in the development and manufacture of MRI radiofrequency coils, which are required components for imaging 129Xe in the MRI system. Polarean Imaging plc was incorporated in 2016 and is based in Durham, North Carolina.
IPO date
Mar 29, 2018
Employees
28
Domiciled in
US
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
891
-13.75%
1,033
-12.86%
1,185
12.17%
Cost of revenue
11,650
13,079
13,402
Unusual Expense (Income)
NOPBT
(10,759)
(12,046)
(12,217)
NOPBT Margin
Operating Taxes
235
(300)
Tax Rate
NOPAT
(10,759)
(12,281)
(11,916)
Net income
(11,885)
-15.95%
(14,141)
3.10%
(13,716)
109.26%
Dividends
Dividend yield
Proceeds from repurchase of equity
18
267
37,308
BB yield
-0.12%
-0.23%
-33.53%
Debt
Debt current
142
142
131
Long-term debt
292
576
849
Deferred revenue
67
129
146
Other long-term liabilities
240
676
316
Net debt
(5,738)
(15,737)
(27,895)
Cash flow
Cash from operating activities
(10,435)
(12,258)
(12,250)
CAPEX
(79)
(64)
(541)
Cash from investing activities
220
(64)
(541)
Cash from financing activities
(140)
148
35,384
FCF
(10,057)
(12,661)
(13,076)
Balance
Cash
6,172
16,454
28,875
Long term investments
Excess cash
6,127
16,403
28,816
Stockholders' equity
(64,546)
(39,983)
(27,285)
Invested Capital
73,368
60,452
59,974
ROIC
ROCE
EV
Common stock shares outstanding
251,207
211,949
196,961
Price
0.06
-88.84%
0.56
-0.88%
0.57
-16.91%
Market cap
15,700
-86.77%
118,691
6.66%
111,283
9.11%
EV
9,962
102,955
83,388
EBITDA
(9,822)
(11,008)
(11,283)
EV/EBITDA
Interest
16
24
21
Interest/NOPBT